0001735276-24-000016.txt : 20240229 0001735276-24-000016.hdr.sgml : 20240229 20240229161650 ACCESSION NUMBER: 0001735276-24-000016 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240227 FILED AS OF DATE: 20240229 DATE AS OF CHANGE: 20240229 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Franchini Indrani Lall CENTRAL INDEX KEY: 0001708764 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36407 FILM NUMBER: 24703886 MAIL ADDRESS: STREET 1: C/O ALEXION PHARMACEUTICALS, INC STREET 2: 100 COLLEGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001178670 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770602661 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 551-8200 MAIL ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020724 4 1 edgardoc.xml PRIMARY DOCUMENT X0508 4 2024-02-27 0 0001178670 ALNYLAM PHARMACEUTICALS, INC. ALNY 0001708764 Franchini Indrani Lall 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 0 1 0 0 EVP, CLO & Secretary 0 Common Stock 2024-02-27 4 M 0 878 0.0 A 4462 D Common Stock 2024-02-28 4 S 0 142 154.54 D 4320 D Common Stock 2024-02-28 4 S 0 111 155.45 D 4209 D Common Stock 2024-02-28 4 S 0 66 156.38 D 4143 D Common Stock 2024-02-28 4 S 0 9 157.3 D 4134 D Common Stock 2024-02-28 4 S 0 1 158.09 D 4133 D Restricted Stock Units 2024-02-27 4 M 0 878 0.0 D 2026-02-27 Common Stock 878 1754 D Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.94 to $154.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.95 to $155.95. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $155.96 to $156.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $157.01 to $157.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date. On February 27, 2023, the reporting person was granted 2,632 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4. By: Stephen Hall, Attorney-in-Fact For: Indrani Franchini 2024-02-29